Background: Cutaneous melanoma affects people at a relatively young age. The possibility of making a screening at the population level is strongly limited because of the high costs and the shortage of well-trained operators. Objective: To evaluate the possibility of a sustainable timetable of screening examinations for cutaneous melanoma. Methods: Subjects who contacted the Lega Italiana per la Lotta contro i Tumori (Italian League against Cancer) between January 2001 and December 2004 were followed up to December 2013 through linkage with the Trento Skin Cancer Registry. The cumulative incidence of cutaneous melanoma was calculated and compared with that observed in the general population. Results: Fifteen newly diagnosed cutaneous melanomas were observed in 3,635 subjects during the screening phase, while 14 new cases were diagnosed within December 2013, in the period of follow-up after the screening. The 95% confidence interval for the cumulative incidence of screened subjects included the cumulative incidence of the general population. No new cutaneous melanomas were detected in a 2-year period, after the first examination, 2 cases within 3 years. Conclusions: Based on our study, we think that in a selected population a screening programme can be performed every 2-3 years. This could help make a screening possible/sustainable for the early diagnosis of cutaneous melanoma in a public health context.

Keywords:
Incidence, Melanoma, Skin cancer, Early diagnosis, Melanoma screening
1.
Davis N: Modern concepts of melanoma and its management. Ann Plast Surg 1978;1:628-629.
2.
Rigel D, Russak J, Friedman R: The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010;60:301-316.
3.
AIRTUM Working Group: Italian cancer figures - report 2011. Survival of cancer patients in Italy. Epidemiol Prev 2011;35(suppl 3):1-200.
4.
Cristofolini M, Piscioli F, Zumiani G: A program for detection of early lesions of cutaneous malignant melanoma in the Province of Trento. Am J Dermopathol 1984;6:283-285.
5.
Cristofolini M, Zumiani G, Boi S, et al: Community detection of early melanoma. Lancet 1986;8473:156.
6.
Cristofolini M, Bianchi R, Boi S, et al: Analysis of the cost-effectiveness ratio of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy. Cancer 1993;71:370-374.
7.
Boi S, Cristofolini M, Micciolo R, et al: Epidemiology of skin tumors: data from the cutaneous cancer registry in Trentino, Italy. J Cutan Med Surg 2003;7:300-305.
8.
Boi S, Cristofolini M, Micciolo R, et al: Incidence and mortality data from cutaneous melanoma in Trentino: registry-based study. J Cutan Med Surg 2008;12:59-63.
9.
Cristofolini M, Boi S, Cattoni D, et al: Voluntary work in the early diagnosis of melanoma. J Eur Acad Dermatol Venereol 2010;24:741-742.
10.
Breslow NE, Day NE: Statistical Methods in Cancer Research. IARC Sci Publ No 82. Lyon, IARC, 1987, vol II: The design and analysis of cohort studies.
11.
Helfand M, Mahon S, Eden K, et al: Screening for skin cancer. Am J Prev Med 2001;20:47-58.
12.
Wolf T, Tai E, Miller T: Screening for skin cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2009;150:194-198.
13.
Ferrini RL, Perlman M, Hill L: American College of Preventive Medicine policy statement. screening for skin cancer. Am J Prev Med 1998;14:80-82.
14.
Koh HK: Melanoma screening. Focusing the public health journey. Arch Dermatol 2007;143:101-103.
15.
Rager EL, Bridgeford EP, Olilla DW: Cutaneous melanoma: update on prevention screening, diagnosis and treatment. Am Family Physician 2005;72:269-276.
16.
Feightner JW: Prevention of skin cancer; in Canadian Task Force on the Periodic Health Examination (eds): The Canadian Guide to Clinical Preventive Health Care. Ottawa, Public Health Agency of Canada, 2006, pp 849-859.
17.
The Cancer Council Australia: National Cancer Prevention Policy 2007-2009. Camperdown (Sydney), The Cancer Council Australia, 2007.
18.
US Preventive Service Task Force: Screening for skin cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:188-193.
19.
Federman DG, Kravetz JD, Kirsner RS: Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol 2002;46:710-714.
20.
Goldberg MS, Doucette JT, Lim HW, et al: Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology national melanoma/skin cancer screening program experience 2001-2005. J Am Acad Dermatol 2007;57:60-66.
21.
De Giorgi V, Grazzini M, Rossari S, et al: Is skin self-examination for cutaneous melanoma detection still adequate? A retrospective study. Dermatology 2012;225:31-36.
22.
Marsden J, Newton-Bishop J, Burrows L, et al: Revised UK guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010;163:238-256.
23.
Argenziano G, Giacomel J, Abramavicus A, et al: Improving triage and management of patients with skin cancer: challenges and considerations for the future. Expert Rev Anticancer Ther 2012;12:609-621.
24.
Losina E, Walensky RP, Geller A, et al: Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007;143:21-28.
25.
From L, Marret L, Rosen C, et al: Screening for skin cancer: a clinical practice guideline. Toronto, Cancer Care Ontario, 2005 Feb program in evidence-based care evidence-based series: 15-1 (in review 2011 Sep).
26.
American Academy of Family Physicians: Summary of Recommendations for Clinical Preventive Services. October 2012.
27.
Welch HG, Woloshin S, Schwartz LM: Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005;331:481.
28.
Rossi CR, Vecchiato A, Bezze G, Mastrangelo G, Montesco MC, Mocellin S, et al: Early detection of melanoma: an educational campaign in Padova, Italy. Melanoma Res 2000;10:181-187.
29.
Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, Volkmer B, Breitbart E: Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012;118:5395-5402.
30.
American Cancer Society: Cancer Facts and Figures 2004. Atlanta, American Cancer Society, 2004.
31.
Registro Clinico Nazionale del Melanoma. http://www.registri-tumori.it.
32.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
33.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds): AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
34.
Schneider JS, Moore DH II, Mendelsohn ML: Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984-1996. J Am Acad Dermatol 2008;58:741-749.
35.
Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-613.
36.
Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, et al: Survival is not the only valuable end point in melanoma screening. J Invest Dermatol 2012;132:1331-1337.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.